{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:13:38Z","timestamp":1790273618622,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA229907"],"award-info":[{"award-number":["1R01CA229907"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recurrence of therapy-resistant tumors is a principal problem in solid tumor oncology, particularly in ovarian cancer. Despite common complete responses to first line, platinum-based therapies, most women with ovarian cancer recur, and eventually, nearly all with recurrent disease develop platinum resistance. Likewise, both intrinsic and acquired resistance contribute to the dismal prognosis of pancreatic cancer. Our previous work and that of others has established CLPTM1L (cleft lip and palate transmembrane protein 1-like)\/CRR9 (cisplatin resistance related protein 9) as a cytoprotective oncofetal protein that is present on the tumor cell surface. We show that CLPTM1L is broadly overexpressed and accumulated on the plasma membrane of ovarian tumor cells, while weakly or not expressed in normal tissues. High expression of CLPTM1L is associated with poor outcome in ovarian serous adenocarcinoma. Robust re-sensitization of resistant ovarian cancer cells to platinum-based therapy was achieved using human monoclonal biologics inhibiting CLPTM1L in both orthotopic isografts and patient-derived cisplatin resistant xenograft models. Furthermore, we demonstrate that in addition to cell-autonomous cytoprotection by CLPTM1L, extracellular CLPTM1L confers resistance to chemotherapeutic killing in an ectodomain-dependent fashion, and that this intercellular resistance mechanism is inhibited by anti-CLPTM1L biologics. Specifically, exosomal CLPTM1L from cisplatin-resistant ovarian carcinoma cell lines conferred resistance to cisplatin in drug-sensitive parental cell lines. CLPTM1L is present in extracellular vesicle fractions of tumor culture supernatants and in patients\u2019 serum with increasing abundance upon chemotherapy treatment. These findings have encouraging implications for the use of anti-CLPTM1L targeted biologics in the treatment of therapy-resistant tumors.<\/jats:p>","DOI":"10.1038\/s41698-021-00152-9","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T11:04:56Z","timestamp":1614683096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L\/CRR9-mediated chemotherapeutic drug resistance"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-8950","authenticated-orcid":false,"given":"Deepak","family":"Parashar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-7919","authenticated-orcid":false,"given":"Anjali","family":"Geethadevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Ebben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis C.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davin R.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunila","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-5179","authenticated-orcid":false,"given":"Brian F.","family":"Volkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Dwinell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-3460","authenticated-orcid":false,"given":"Pradeep","family":"Chaluvally-Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8112-1108","authenticated-orcid":false,"given":"Michael A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"152_CR1","doi-asserted-by":"crossref","unstructured":"Pommier, A. et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science 360, eaao4908 (2018).","DOI":"10.1126\/science.aao4908"},{"key":"152_CR2","doi-asserted-by":"crossref","unstructured":"Clarke, W. R., Amundadottir, L. & James, M. A. CLPTM1L\/CRR9 Ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells. Int. J. Cancer 144, 1367\u20131378 (2018).","DOI":"10.1002\/ijc.32012"},{"key":"152_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1158\/1535-7163.MCT-15-0774","volume":"15","author":"JB Gifford","year":"2016","unstructured":"Gifford, J. B. et al. Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 15, 1043\u20131052 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"152_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184110","volume":"12","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs). PLoS ONE 12, e0184110 (2017).","journal-title":"PLoS ONE"},{"key":"152_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1562-z","volume":"16","author":"PC Thakur","year":"2018","unstructured":"Thakur, P. C. et al. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J. Transl. Med. 16, 190 (2018).","journal-title":"J. Transl. Med"},{"key":"152_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19339-5","volume":"8","author":"JC Santos","year":"2018","unstructured":"Santos, J. C. et al. Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci. Rep. 8, 829 (2018).","journal-title":"Sci. Rep."},{"key":"152_CR7","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2217\/nnm-2017-0184","volume":"12","author":"A Sharma","year":"2017","unstructured":"Sharma, A. Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomed. (Lond.) 12, 2137\u20132148 (2017).","journal-title":"Nanomed. (Lond.)"},{"key":"152_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/bjc.2017.18","volume":"116","author":"GK Patel","year":"2017","unstructured":"Patel, G. K. et al. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. Br. J. Cancer 116, 609\u2013619 (2017).","journal-title":"Br. J. Cancer"},{"key":"152_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0755-z","volume":"17","author":"J Qiu","year":"2018","unstructured":"Qiu, J. et al. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Mol. Cancer 17, 2 (2018).","journal-title":"Mol. Cancer"},{"key":"152_CR10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-13-1617","volume":"74","author":"MA James","year":"2014","unstructured":"James, M. A., Vikis, H. G., Tate, E., Rymaszewski, A. L. & You, M. CRR9\/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis. Cancer Res. 74, 1116\u20131127 (2014).","journal-title":"Cancer Res"},{"key":"152_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036116","volume":"7","author":"MA James","year":"2012","unstructured":"James, M. A. et al. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS ONE 7, e36116 (2012).","journal-title":"PLoS ONE"},{"key":"152_CR12","doi-asserted-by":"crossref","unstructured":"Puskas, L. G. et al. Novel anti-CRR9\/CLPTM1L antibodies with antitumorigenic activity inhibit cell surface accumulation, pi3k interaction, and survival signaling. Mol. Cancer Ther. 15, 985\u2013997 (2016).","DOI":"10.1158\/1535-7163.MCT-15-0717"},{"key":"152_CR13","doi-asserted-by":"crossref","unstructured":"Trezise, S. et al. Mining the plasma cell transcriptome for novel cell surface proteins. Int. J. Mol. Sci. 19, 2161 (2018).","DOI":"10.3390\/ijms19082161"},{"key":"152_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1074\/mcp.M112.018135","volume":"11","author":"RL Gundry","year":"2012","unstructured":"Gundry, R. L. et al. A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells. Mol. Cell Proteom. 11, 303\u2013316 (2012).","journal-title":"Mol. Cell Proteom."},{"key":"152_CR15","doi-asserted-by":"crossref","unstructured":"Jia, J. et al. CLPTM1L promotes growth and enhances aneuploidy in pancreatic cancer cells. Cancer Res. 74, 2785\u20132795 (2014).","DOI":"10.1158\/0008-5472.CAN-13-3176"},{"key":"152_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052598","volume":"7","author":"Z Ni","year":"2012","unstructured":"Ni, Z. et al. CLPTM1L is overexpressed in lung cancer and associated with apoptosis. PLoS ONE 7, e52598 (2012).","journal-title":"PLoS ONE"},{"key":"152_CR17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1006\/bbrc.2001.4250","volume":"280","author":"K Yamamoto","year":"2001","unstructured":"Yamamoto, K., Okamoto, A., Isonishi, S., Ochiai, K. & Ohtake, Y. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem. Biophys. Res Commun. 280, 1148\u20131154 (2001).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"152_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27521-y","volume":"8","author":"A Nagy","year":"2018","unstructured":"Nagy, A., Lanczky, A., Menyhart, O. & Gyorffy, B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci. Rep. 8, 9227 (2018).","journal-title":"Sci. Rep."},{"key":"152_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ejmg.2013.01.002","volume":"56","author":"G Izzo","year":"2013","unstructured":"Izzo, G. et al. A microduplication of 5p15.33 reveals CLPTM1L as a candidate gene for cleft lip and palate. Eur. J. Med. Genet. 56, 222\u2013225 (2013).","journal-title":"Eur. J. Med. Genet."},{"key":"152_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/geno.1998.5577","volume":"54","author":"K Yoshiura","year":"1998","unstructured":"Yoshiura, K. et al. Characterization of a novel gene disrupted by a balanced chromosomal translocation t(2;19)(q11.2;q13.3) in a family with cleft lip and palate. Genomics 54, 231\u2013240 (1998).","journal-title":"Genomics"},{"key":"152_CR21","doi-asserted-by":"publisher","first-page":"16752","DOI":"10.1073\/pnas.0907939106","volume":"106","author":"JP da Cunha","year":"2009","unstructured":"da Cunha, J. P. et al. Bioinformatics construction of the human cell surfaceome. Proc. Natl Acad. Sci. USA 106, 16752\u201316757 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"152_CR22","first-page":"649","volume":"21","author":"J Colombo","year":"2009","unstructured":"Colombo, J. et al. Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma. Oncol. Rep. 21, 649\u2013663 (2009).","journal-title":"Oncol. Rep."},{"key":"152_CR23","doi-asserted-by":"crossref","unstructured":"Mobuchon, L. et al. A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus. NPJ Genom. Med. 2, 5 (2017).","DOI":"10.1038\/s41525-017-0008-5"},{"key":"152_CR24","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.2147\/OTT.S138956","volume":"10","author":"HW Lee","year":"2017","unstructured":"Lee, H. W. et al. TERT-CLPTM1 locus polymorphism (rs401681) is associated with the prognosis of hepatocellular carcinoma. Onco Targets Ther. 10, 4853\u20134858 (2017).","journal-title":"Onco Targets Ther."},{"key":"152_CR25","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10620-014-3433-7","volume":"60","author":"R Zhang","year":"2015","unstructured":"Zhang, R. et al. Upregulation of miR-494 inhibits cell growth and invasion and induces cell apoptosis by targeting cleft lip and palate transmembrane 1-like in esophageal squamous cell carcinoma. Dig. Dis. Sci. 60, 1247\u20131255 (2015).","journal-title":"Dig. Dis. Sci."},{"key":"152_CR26","doi-asserted-by":"publisher","first-page":"11917","DOI":"10.18632\/oncotarget.14440","volume":"8","author":"J Crow","year":"2017","unstructured":"Crow, J. et al. Exosomes as mediators of platinum resistance in ovarian cancer. Oncotarget 8, 11917\u201311936 (2017).","journal-title":"Oncotarget"},{"key":"152_CR27","doi-asserted-by":"crossref","unstructured":"Zhang, H. D. et al. Exosome: a novel mediator in drug resistance of cancer cells. Epigenomics 10,1499\u20131509 (2018).","DOI":"10.2217\/epi-2017-0151"},{"key":"152_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0659-y","volume":"16","author":"X Li","year":"2017","unstructured":"Li, X. & Wang, X. The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer. Mol. Cancer 16, 92 (2017).","journal-title":"Mol. Cancer"},{"key":"152_CR29","unstructured":"\u201cGuidance for industry: for the submission of chemistry, manufacturing and controls and establishment description information for human blood and blood components intended for transfusion or for further manufacture and for the completion of the form FDA 356h, \u2018application to market a new drug, biologic or an antibiotic drug for human use;\u2019\u201c availability. Food and Drug Administration, HHS. Notice. Fed. Regist. 64, 25049\u201325050 (1999)."},{"key":"152_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/labinvest.2016.146","volume":"97","author":"I Roy","year":"2017","unstructured":"Roy, I. et al. Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. Lab Invest 97, 302\u2013317 (2017).","journal-title":"Lab Invest"},{"key":"152_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/cgt.2013.32","volume":"20","author":"S Saini","year":"2013","unstructured":"Saini, S. et al. Gene silencing of A-kinase anchor protein 4 inhibits cervical cancer growth in vitro and in vivo. Cancer Gene Ther. 20, 413\u2013420 (2013).","journal-title":"Cancer Gene Ther."},{"key":"152_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1756-9966-32-69","volume":"32","author":"A Sinha","year":"2013","unstructured":"Sinha, A. et al. Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy. J. Exp. Clin. Cancer Res. 32, 69 (2013).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"152_CR33","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.974382","volume":"3","author":"S Agarwal","year":"2014","unstructured":"Agarwal, S. et al. Sperm associated antigen 9 (SPAG9) expression and humoral response in benign and malignant salivary gland tumors. Oncoimmunology 3, e974382 (2014).","journal-title":"Oncoimmunology"},{"key":"152_CR34","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1038\/s41388-020-1194-7","volume":"39","author":"C Chen","year":"2020","unstructured":"Chen, C. et al. ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R\/STAT3 signaling axis. Oncogene 39, 2921\u20132933 (2020).","journal-title":"Oncogene"},{"key":"152_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-015-0258-y","volume":"34","author":"N Jagadish","year":"2015","unstructured":"Jagadish, N. et al. A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer. J. Exp. Clin. Cancer Res. 34, 142 (2015).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"152_CR36","doi-asserted-by":"crossref","unstructured":"Jagadish, N. et al. Heat shock protein 70-2 (HSP70-2) is a novel therapeutic target for colorectal cancer and is associated with tumor growth. BMC Cancer 16, 561 (2016).","DOI":"10.1186\/s12885-016-2592-7"},{"key":"152_CR37","doi-asserted-by":"publisher","first-page":"13101","DOI":"10.1007\/s13277-016-5240-6","volume":"37","author":"N Jagadish","year":"2016","unstructured":"Jagadish, N. et al. Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells. Tumour Biol. 37, 13101\u201313110 (2016).","journal-title":"Tumour Biol."},{"key":"152_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081348","volume":"8","author":"D Kanojia","year":"2013","unstructured":"Kanojia, D. et al. Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma. PLoS ONe 8, e81348 (2013).","journal-title":"PLoS ONe"},{"key":"152_CR39","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1016\/j.celrep.2019.11.085","volume":"29","author":"D Parashar","year":"2019","unstructured":"Parashar, D. et al. miRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. Cell Rep. 29, 4389\u20134406 (2019). e4310.","journal-title":"Cell Rep."},{"key":"152_CR40","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/1535-7163.MCT-12-0494","volume":"11","author":"T Takekoshi","year":"2012","unstructured":"Takekoshi, T., Ziarek, J. J., Volkman, B. F. & Hwang, S. T. A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. Mol. Cancer Therapeutics 11, 2516\u20132525 (2012).","journal-title":"Mol. Cancer Therapeutics"},{"key":"152_CR41","doi-asserted-by":"crossref","unstructured":"Agarwal, S. et al. The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. Oncoimmunology 2, e24270 (2013).","DOI":"10.4161\/onci.24270"},{"key":"152_CR42","doi-asserted-by":"publisher","unstructured":"Parashar, D. et al. Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L\/CRR9-mediated chemotherapeutic drug resistance. figshare https:\/\/doi.org\/10.6084\/m9.figshare.13379873 (2020).","DOI":"10.6084\/m9.figshare.13379873"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00152-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00152-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00152-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:48:30Z","timestamp":1670093310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-021-00152-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1038\/s41698-021-00152-9","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. James is an inventor on pending and awarded patents related to anti-CLPTM1L agents used in these studies and the founder of Essential Biotechnology LLC. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}